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Objective. To assess diﬀerences in age of onset, hypertension duration, type of drug, treatment compliance, and salt-free diet
compliance between patients with stroke and myocardial infarction. Patients and Methods. The study was conducted in 3 hospitals
in Baghdad between June 2010 and June 2011. First group includes 81 stroke patients (36 females and 45 males), age ranges
between(33–82years).Secondgroupincludes110myocardialinfarctionpatients(46femalesand64males),agesrangesfrom(23–
76 years). Results. Salt-free diet noncompliance was seen in 69% and 62% of Myocardial infarction and stroke groups, respectively.
Silent hypertension was seen in 6.3% and 19.7% of myocardial infarction and stroke groups, respectively. Noncompliant on
antihypertensive therapy was seen in 61%, 71%, and 48% of the total, myocardial infarction, and stroke groups, respectively.
The drug type was 24% angiotensin converting enzyme inhibitor, 18.8% combined drugs, 16.2% Beta Blocker, 11% angiotensin
11 receptor blocker, 10.4% calcium channel blocker and 7.3% diuretic. In stroke group, the commonest drug was 23% angiotensin
converting inhibitor and the least (5%) was angiotensin receptor blocker. In myocardial infarction group, the commonest drug
was 25% Angiotensin Converting Inhibitor and the least (8%) was diuretic. Discussion and Conclusion. Silent hypertension was
high in Iraq. Salt-free diet noncompliance was high in both groups; drug noncompliance was signiﬁcantly higher in patients with
myocardial infarction. Angiotensin 11 receptor blocker use was associated signiﬁcantly with myocardial infarction more than in
stroke.
1.Introduction
Hypertension is a progressive cardiovascular syndrome aris-
ing from complex etiologies. Early markers of the syndrome
are often present before persistent blood pressure elevation.
Progression is strongly associated with functional and struc-
tural abnormalities that damage the heart, kidneys, brain,
and vasculature [1].
Based on population-based survey conducted in 1979
arterial hypertension comprises 12% of the Iraqi population
[2]. After that, there is only small report from selected
Primary Health Care Centers in Nasiriya city south of Iraq,
reported 46.1% of study population were hypertensive [3].
Hospitals morbidity data provided by Iraqi Ministry of
Health in 2004 demonstrates a 65% increase of the hospital
admission due to coronary heart disease (CHD) and stroke
and more than a ﬁvefold increase in outpatient visits with
the same diagnosis between 1989 and 1999. The major
antihypertensive drugs are provided to the patients in Iraq
by special cards freely in the primary health centers, yet this
supply frequently was insuﬃcient and interrupted [2].
In developed countries arterial hypertension is the most
prevalent cardiovascular disorder modiﬁable risk factor; it
aﬀects about 20% to 50% of the adult population in these
countries [4, 5]. Hypertension increases the risk of stroke
by sevenfold more than general population, and strict blood
pressure control can decrease the risk of recurrent stroke by
one third [5–7]. For every 20-mmHg systolic or 10-mmHg
diastolic increase in BP, there is a doubling of mortality from
both coronary heart disease and stroke [8–10].2 International Journal of Hypertension
Despite advances in the understanding of the hyperten-
sion pathophysiology and the availability of eﬀective treat-
ment strategies, the rate of blood pressure control is still very
low and the reasons for that include poor health awareness,
poordietarysystem,andnoncomplianceonthedrugtherapy
[4–6].
The aim of the study is to evaluate hypertension dura-
tion, type of antihypertensive drug, antihypertensive treat-
ment compliance, and salt-free diet compliance, as well as
the age at onset of hypertension in group of patients with
acute myocardial infarction and group of patients with
acute ischemic stroke, and to assess the diﬀerences in those
parameters between both groups.
2. Patientsand Methods
The study is cross-sectional comparative study involving
one-hundred and ninety-one hypertensive patients; the pa-
tients were from 2 groups, the ﬁrst group was the acute
ischemic stroke patients with hypertension which includes
81 consecutive patients (36 females and 45 males), and
their ages were between 33–82 years. The second group was
the acute myocardial infarction patients with hypertension
which includes 110 consecutive patients (46 females and 64
males), and their ages ranges from 23–76 years. The study
was conducted in neurosciences hospital, Al-kindy Teaching
HospitalandIbnAlbitarCardiacCenterinBaghdadbetween
June 2010 and June 2011. The selection of patients does
not diﬀer in these diseases between general and specialized
centers as the stroke and coronary heart disease patients
were admitted into each hospital as an emergency cases.
Each patient with those diseases was asked about his chronic
disease treatment cards which are provided for patients with
chronic diseases in the primary health centers and was asked
and assessed clinically for hypertension.
The criteria for inclusion of the ﬁrst group were all
patients admitted with acute ischemic stroke with history
of hypertension or patients with no history of hypertension
but having retinal stigmata of hypertension or ECG changes
suggestive of hypertension. We exclude any patient with
suspicious diagnosis of space occupying lesion.
The criteria for inclusion of the second group were all
patientsadmittedwithacutemyocardialinfarctionprovedby
ECG and cardiac enzymes; all types of myocardial infarction
were included; there should be history of hypertension or
retinal stigmata of hypertension or ECG changes suggestive
of hypertension in those who deny history of hypertension.
Patients with coexisting myocardial infarction and ischemic
stroke were excluded from the study.
All patients were asked about age of hypertension
onset, hypertension duration, type of antihypertensive drug
treatment, antihypertensive treatment compliance, and salt-
free diet compliance. These data were also documented by
reviewing the patient primary health care chronic disease
card. The patients were examined physicallyand ophthalmo-
scopically.
All patients had ECG testings during their admissions;
brain CT scanning was done for all stroke patients. The data
about drug and diet was taken from the patients and their
Table 1: Gender distribution, salt-free diet compliance, and age
below 40 years in patients with myocardial infarction and ischemic
stroke.
Myocardial
infarction Ischemic stroke P value
Gender male 64/110 (58%) 45/81 (55.5%) P = 0.4
Gender female 46/110 (42%) 36/81 (44.5%) P = 0.4
Salt-free diet
compliance 34 110 (31%) 31/81 (38%) P = 0.35
Below 40 years 24/110 (22%) 6/81 (7%) P = 0.0083
relatives, and the patients were considered noncompliant
on drug when there are frequent interruptions in their dug
intake, all patients had been advised for salt-free diet, and
patient considered noncompliant when the patient eat nor-
mal salt diet. The patient was considered as silent hyperten-
sive when there is no past history of hypertension, but the
patient has retinal stigmata of hypertension or ECG changes
suggestive of hypertension.
The data was tabulated using Microsoft Excel 2007, and
statistical diﬀerences were assessed using graph pad software
(quick calc site for scientist). Fisher’s test was used to assess
thestatisticaldiﬀerencesforcategoricaldata,andMcNemar’s
testwasusedtocompareproportionsdiﬀerences.P valueless
than 0.05 was considered signiﬁcant.
3. Results
The male involvement from both groups’ total patients was
57%; male forms 58% and 55.5% of Myocardial infarction
and Ischemic stroke groups respectively (Table 1). The
female ratio were 42% and 44.5% of myocardial infarction
and ischemic stroke groups, respectively (Table 1).
Salt-free diet noncompliance was seen in 69% and
62% of myocardial infarction and ischemic stroke groups,
respectively (Table 1). Ages below 40 years were seen in 22%
and 7% of myocardial infarction and ischemic stroke groups,
respectively (Table 1).
Duration of hypertension between 6 to 10 years was seen
in57outof110and41outof81ofmyocardialinfarctionand
ischemic stroke groups, respectively, other durations were
seen in Table 2.
Patients not known as hypertensive previously and dis-
covered only by retinal stigmata and ECG changes of old
hypertension form 23 out of the total 191 of both groups
(12%); 7 out of 110 (6.3%) and 16 out of 81 (19.7%) of
myocardial infarction and ischemic stroke groups, respec-
tively, were not known as hypertensive previously (Table 3).
Noncompliance on antihypertensive therapy was seen in
61% out of the total 191 of both groups; 71% and 48%
myocardial infarction and ischemic stroke groups, respec-
tively, were not compliant on antihypertensive therapy
(Table 3).
The total drug treatment types were 24% angiotensin
converting inhibitor, 18.8% combined drugs, 16.2% beta
blocker, 11% angiotensin receptor blocker, 10.4% CA chan-
nel blocker and 7.3% diuretic (Table 4). The drug treatmentInternational Journal of Hypertension 3
Table 2: Duration of hypertension in both myocardial infarction ischemic stroke groups.
Not known as
hypertensive Up to 5 years 6–10 11–15 More than 16 Total
Myocardial infarction 7 (6%) 3 (2.7%) 57 (52%) 34 (31%) 9 (8%) 110
Ischemic stroke 16 (20%) 2 (2.4%) 41 (50.6%) 19 (23.4%) 3 (3.7%) 81
Total 23 (12%) 5 (2.6%) 98 (51%) 53 (27.7%) 12 (6.2%) 191
P value Less than 0.0009 0.3 0.2 0.4 0.2
Table 3: Treatment compliance and no treatments in both groups of myocardial infarction and ischemic stroke.
No treatment Not compliant Compliant Total
Myocardial infarction 7 (6%) 78 (71%) 25 (22%) 110
Ischemic stroke 16 (19.7%) 39 (48%) 26 (32.3%) 81
Total 23 (12%) 117 (61%) 51 (27%) 191
P value P value equals 0.0009 P value is less than 0.0001 P value equals 0.0021
Table 4: Treatment drugs type in both groups of Myocardial infarction and stroke.
Angiotensin
receptor blocker
Angiotensin
converting
inhibitor
Beta blocker Diuretics CA channel
blocker Combined No. of
treatment Total
Myocardial infarction 17/110
15%
27/110
25%
19/110
17%
9/110
8%
12/110
10%
19/110
19%
7/110
6% 110
Ischemic stroke 4/81
5%
19/81
23%
12/81
15%
5/81
6%
8/81
10%
17/81
21%
16/81
20% 81
Total 21/191
11%
46/191
24%
31/191
16.2%
14/191
7.3%
20/191
10.4%
36/191
18.8%
23/191
12% 191
(odds ratio)
(95% conﬁdence
interval)
P value
(0.990)
(0.740– 1.324)
P = 0.022
(1.146)
(0.85–1.54)
P = 0.385
(1.17)
(0.87–1.57)
P = 0.3
(1.247)
(0.92–1.67)
P = 0.14
(0.54)
(0.42–0.69)
P = 0.08
(1.301)
(0.96–1.75)
P = 0.082
(1.653)
(1.223–2.247)
P = 0.0009
type in myocardial infarction with hypertension cases were
25% angiotensin converting inhibitor, 19% combined drugs,
17%betablocker,15%angiotensinreceptorblocker,10%CA
channel blocker and 8% diuretic (Table 4).
The drug treatment type in ischemic stroke with hyper-
tension cases was 23% Angiotensin Converting Inhibitor,
21% combined drugs, 15% Beta Blocker, 10% CA Channel
Blocker, 6% diuretic and 5% angiotensin Receptor Blocker
(Table 4).
4. Discussion
The prevalence of hypertension was widely variable in dif-
ferentsocieties;itwasrangedfrom3%to73%[8].Hyperten-
sion forms a very big medical problem in Iraq, The present
study showed male involvements were higher than females
in both ischemic stroke and myocardial infraction groups;
this is related to higher male prevalence in both of these
diseases and not reﬂecting higher hypertension prevalence
in male gender; this is in agreement with higher male gen-
der reported by Zdrojewski et al. in NATPOL III study [11].
Many reports from diﬀerent countries reported higher fe-
male prevalence rate of hypertension [10, 12].
The salt-free diet noncompliance rate was seen in 69%
and 62% of the myocardial infarction and ischemic stroke
groups, respectively; there is no statistical diﬀerence of both
rates in both groups; those rates represent a major reason for
diﬃcult to control treatment of the high blood pressure and
later complications like stroke and ischemic heart disease.
This high rate was in agreement with studies done in USA,
which suggest strategies to reduce sodium intake on a pop-
ulation level to reduce stroke and MI incidence [13, 14].
Many clinicians emphasize that not the level of salt intake
but salt sensitivity of blood pressure which predicts the eﬀect
of salt restriction in the individual treatment of essential
hypertension [15].
Silent hypertension is the asymptomatic cases that car-
ry only stigmata of hypertension on ECG and retinal ex-
amination, it was reported in 12% of the sample in the
present study, and it forms 6% and 19.7% of the myocardial
infarction and ischemic stroke groups, respectively. The
silenthypertensionwassigniﬁcantlyassociatedwithischemic
stroke rather than ischemic heart disease. We did not
ﬁnd an explanation for this higher risk of stroke in silent
hypertension. The silent hypertension in the present study
was less than the 20% that was reported in the survey of4 International Journal of Hypertension
hypertension in Iraq in 1979 [3]. Awareness of hypertension
was reported in 46% of one meta-analysis and varied from
25.2% in Korea to 75% in Barbados; [10]. Also in USA,
More than 25% of adults were unaware of their diagnosis
[16]. All the above results of unawareness of hypertension
were higher than the present study results; this is related to
many factors including easy access and availability of blood
pressure measurement in private and governmental clinics
and too many nursing small booths available everywhere in
Iraq.
The present study showed a statistically higher rate of
cardiac infarction below 40 years. This was related to serious
increased prevalence of hypertension and other risk factors
such as lack of smoking preventions laws as well as more
stressful life events and insecure life style in Iraq.
The rate of the noncompliance was seen in 61%, 71%
and 48% of the total sample, the myocardial infarction, and
ischemic stroke groups, respectively. Those rates were higher
than Al-lami result and AL-Dabbagh results [3, 17]. our
higher results is correlated to sampling error as our sample
represents a complicated hypertension disease with stroke
and myocardial infraction, whereas other samples represent
hypertension without ischemic stroke or myocardial infrac-
tion. Noncompliance was signiﬁcantly higher in patients
with myocardial infarction (P = less than 0.0001) more than
ischemic stroke.
The present study showed the rate of antihypertensive
drug prescription was angiotensin converting inhibitor 24%,
combined 18.8%, beta blocker 16.2%, angiotensin receptor
blocker 11%, CA channel blocker 10.4%, and diuretics 7.3%.
These rates of treatment strategy were diﬀerent from Bajrak-
tari et al. who found the angiotensin-converting enzyme
inhibitors (ACEIs) and/or angiotensin II receptor blockers
werethedrugsmostcommonlyprescribedinhisstudygroup
(83%). β-blockers (BB) were the second group of the drugs
that were prescribed (71%), followed by diuretics (60%),
and calcium channel blockers (26%) [18]. The diﬀerences
in treatment modalities between the 2 studies are related to
socioeconomic diﬀerences between the two societies.
The present study showed myocardial infarction was
signiﬁcantlyassociatedwithhighrateofangiotensinreceptor
blocker use in comparison to stroke group (P = 0.022).
The diﬃculties facing the progress of the present study
were unavailability of recent Iraqi other studies in this ﬁeld
because of the continuous war events in Iraq since 1982, the
smallness of the sample size was because we did not include
patients not having hypertension, those with coexisting
stroke, and coronary heart disease, and many patients with
severe stroke and coronary heart disease were unable, and
refuse to participate in the study. The sample small size
imposed us to use proportions and to use McNemar’s test
to compare diﬀerences between proportions.
5. Conclusion
There was high rate of salt-free noncompliance in both
myocardial infarction and ischemic stroke groups. Silent
hypertension forms 6% and 19.7% of the myocardial
infarction and ischemic stroke groups, respectively. There is
high rate of young below 40 age of myocardial infarction
with hypertension patients more than the stroke patients.
T h en o n c o m p l i a n c ew a ss e e ni nv e r yh i g hp e r c e n t a g eo f
both groups, and noncompliance was signiﬁcantly higher in
patients with myocardial infarction. Drugs most commonly
used were angiotensin converting inhibitor in 24%, com-
bined in 18.8%, beta blocker in 16.2%, angiotensin receptor
blocker in 11%, CA channel blocker in 10.4%, and diuretics
in 7.3%.
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